[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635877":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":41,"responsibleParty":158,"collaborators":160,"id":163,"slug":25,"hasResults":164,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":164,"sex":169,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":25,"studyType":175,"phases":176,"briefSummary":178,"conditions":179,"keywords":184,"overallStatus":189,"whyStopped":25,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":199},{"fullName":5,"class":6},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Control","OTHER","Standard of care for the first 8 weeks then visual stimulation for the following 8 weeks",[13,14],"Device: Visual Stimulation","Other: standard of care",{"label":16,"type":10,"description":17,"interventionNames":18},"Intervention","Visual stimulation for the first 8 weeks then standard of care for the following 8 weeks",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Visual Stimulation","Our audiovisual stimulation procedure IVR, called 3D-MOT, was encoded using the the 3D Unity programming platform and deployed in HMDs with built-in head\u002Feye tracking. We implemented the multiple object tracking (MOT) paradigm, developed in the 80's to study visual attention in humans, and added correlated spatial sound.",[9,16],null,{"type":10,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"standard of care","During this phase, the patients will be at home without a headset and will not be exposed to an audio-visual stimulation task in virtual reality.",[9,16],[31,37],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},"Michael Reber, PhD","CONTACT","+33 388116648","17675","michael.reber@inserm.fr",{"name":38,"role":33,"phone":39,"phoneExt":25,"email":40},"Natacha Entz-Werle, Pr","0388128396","Natacha.Entz-Werle@chru-strasbourg.fr",[42,58,73,85,100,113,128,143],{"facility":43,"status":25,"city":44,"state":25,"zip":25,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Department of Paediatric and adolescents medicine, Medical University","Vienna","Austria","AT",{"type":48,"coordinates":49},"Point",[50,51],16.37208,48.20849,{"lat":51,"lon":50},[54],{"name":55,"role":33,"phone":56,"phoneExt":25,"email":57},"Amadeo Azizi, Pr","4314040032320","amedeo.azizi@meduniwien.at",{"facility":59,"status":25,"city":60,"state":25,"zip":25,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Paediatrics and Adolescents Medicine, University Hospital","Copenhagen","Denmark","DK",{"type":48,"coordinates":64},[65,66],12.56553,55.67594,{"lat":66,"lon":65},[69],{"name":70,"role":33,"phone":71,"phoneExt":25,"email":72},"Astrid Sehested, Pr","04535451367","astrid.marie.sehested@regionh.dk",{"facility":74,"status":25,"city":75,"state":25,"zip":25,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Hôpital de Hautepierre","Strasbourg","France","FR",{"type":48,"coordinates":79},[80,81],7.74553,48.58392,{"lat":81,"lon":80},[84],{"name":38,"role":33,"phone":39,"phoneExt":25,"email":40},{"facility":86,"status":25,"city":87,"state":25,"zip":25,"country":88,"countryCode":89,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Institute of Tumour, department of haematology and Oncohaematology paediatric","Milan","Italy","IT",{"type":48,"coordinates":91},[92,93],12.59836,42.78235,{"lat":93,"lon":92},[96],{"name":97,"role":33,"phone":98,"phoneExt":25,"email":99},"Elisabetta Schiavello, Dr","390223902588","elisabetta.schiavello@istitutotumori.mi.it",{"facility":101,"status":25,"city":102,"state":25,"zip":25,"country":88,"countryCode":89,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Paediatric Haematology, University Hospital","Padova",{"type":48,"coordinates":104},[105,106],11.14261,44.38225,{"lat":106,"lon":105},[109],{"name":110,"role":33,"phone":111,"phoneExt":25,"email":112},"enrico Opocher, Dr","390498211493","enrico.opocher@aopd.veneto.it",{"facility":114,"status":25,"city":115,"state":25,"zip":25,"country":116,"countryCode":117,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Princess Maxima Centre for Paediatric Oncology","Utrecht","Netherlands","NL",{"type":48,"coordinates":119},[120,121],5.12222,52.09083,{"lat":121,"lon":120},[124],{"name":125,"role":33,"phone":126,"phoneExt":25,"email":127},"Lisethe Meijer, Dr","00 31 6 5000 6503","l.meijer-13@prinsesmaximacentrum.nl",{"facility":129,"status":25,"city":130,"state":25,"zip":25,"country":131,"countryCode":132,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"Paediatric Oncology, San Joan de Deu","Barcelona","Spain","ES",{"type":48,"coordinates":134},[135,136],2.15899,41.38879,{"lat":136,"lon":135},[139],{"name":140,"role":33,"phone":141,"phoneExt":25,"email":142},"Miriam Pavon, Dr","34610570117","miriam.pavon@sjd.es",{"facility":144,"status":25,"city":145,"state":25,"zip":25,"country":146,"countryCode":147,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"Great Ormond Street Hospital for Children","London","United Kingdom","UK",{"type":48,"coordinates":149},[150,151],-0.12574,51.50853,{"lat":151,"lon":150},[154],{"name":155,"role":33,"phone":156,"phoneExt":25,"email":157},"Darren Pr Hargrave","0442078298832","d.hargrave@ucl.ac.uk",{"type":159,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[161],{"name":162,"class":10},"Fight Kids Cancer","100635877",false,"NCT07558395","Effectiveness of a Visual Telerehabilitation Program on Visual Perception in Children, Adolescents and Young Adults With Hemianopsia Consecutive to a Brain Tumour","REVIIH-BT","Inclusion Criteria:\n\n* Male and Female\n* 10 - 40 years old\n* Diagnosed hemianopsia (\\>12 months)\n* History of diagnosis brain tumour\n* Being stable for the tumour for \\> 6 months (either on therapy or not)\n* Visual acuity ≤ 0.7 LogMAR\n* Ability to follow the visual and auditory stimuli and training instructions\n* Home WiFi access\n* Ability to attend all on site visits\n* Affiliation to the Social Security or beneficiary of such social protection\n\nExclusion Criteria:\n\n* Age\\\u003C 10 years old of \\> 40 years old\n* Ocular disease\n* Inability to perform during testing or training\n* 3 consecutive VRISE scores \\\u003C 25 at inclusion\n* History of vertigo\n* Prior vision rehabilitation interventions\n* Recreational or medicinal consumption of psychoactive drugs\n* Persons under court protection\n* Interpupillary distance \\\u003C 54mm","ALL","10 Years","40 Years",{"count":173,"type":174},120,"ESTIMATED","INTERVENTIONAL",[177],"NA","Evaluate the efficiency of audiovisual stimulation in virtual reality for improving the visual perception of children, adolescents, and young adults with hemianopia resulting from pediatric brain tumors. These individuals can lose up to 50% of their visual field, significantly impacting their independence, mobility, and daily lives.",[180,181,182,183],"Hemianopsia","Virtual Reality","Visual Rehabilitation","Pediatric Brain Tumor",[185,186,187,188],"brain tumor","pediatric","visual rehabilitation","virtual reality","NOT_YET_RECRUITING","2026-04-23",{"date":192,"type":193},"2026-04-30","ACTUAL",{"date":195,"type":174},"2026-05-15",{"date":197,"type":174},"2029-09",{"name":5,"class":6},8]